News
PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Signed Exclusive Licensing Agreement for Commercialization of D-PLEX100 in Europe for Potentially Over $110 Million in Upfront and Milestone Payments, Plus Royalties on Net SalesIndependent Data Safety Monitoring Board Recommended Concluding Phase 3 SHIELD I Trial of...
PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX in Europe
PolyPid to potentially receive over $110 million in upfront and milestone payments as well as royalties on net sales ADVANZ PHARMA to receive exclusive rights to commercialize D-PLEX100 for the prevention of surgical site infections in abdominal and cardiac surgeries...
PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022
PETACH TIKVA, Israel, July 27, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2022 financial results and operational...
PolyPid Announces Presentation of Phase 2 D-PLEX Clinical Data at the Midwest Surgical Association 2022 Annual Meeting
Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium Presentation PETACH TIKVA, Israel, July 25, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a...
PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO
Company Previously Announced Planned CEO Transition Following Retirement of Amir WeisbergPETACH TIKVA, Israel, July 05, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, announced...
PolyPid Hosting Key Opinion Leader Webinar on Managing the Cost of Surgical Site Infections
PETACH TIKVA, Israel, June 15, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a key opinion leader ("KOL") webinar on the cost of managing surgical...
PolyPid Announces Presentation of D-PLEX Phase 2 Clinical Data at ASM Microbe 2022
Phase 2 clinical data on the efficacy of D-PLEX100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation PETACH TIKVA, Israel, June 06, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a...
PolyPid to Present at the JMP Securities 2022 Life Sciences Conference
PETACH TIKVA, Israel, June 02, 2022 -- PolyPid Ltd. (Nasdaq: PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the JMP Securities 2022 Life Sciences Conference, which is...
PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects
Locally Administered Docetaxel Through Extended-Release Delivery via the Company's PLEX Technology Offers Potentially Enhanced Adjuvant Chemotherapy Option PETACH TIKVA, Israel, June 01, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage...
PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX for Prevention of Surgical Site Infections in Abdominal Surgery
Following Unblinded Interim Efficacy Analysis, Data Safety Monitoring Board Recently Recommended Concluding Study at 950 Patients, the Minimum Number of Patients TargetedTop-line Results Expected by End of Q3 2022; Potential NDA and MAA Submissions Targeted for H1...